



TÜBINGEN, Deutschland/ BOSTON, USA, March 17, 2020

**Invitation to press briefing (conference call) on March 17, 2020  
Current Developments at CureVac**

Dear Madam or Sir,

You are cordially invited to attend a telephone press briefing today to discuss CureVac's approach to developing a vaccine to prevent infection with SARS-CoV-2 as well as recent company events.

**Date: Today, Tuesday, March 17, 2020**

**Time: 2:00 pm CET / 9:00 AM EDT**

**Registration and dial-ins:**

<https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=9927930&linkSecurityString=a693ece70>

The audio conference call will be held in English and no presentation will be provided. Participants are kindly requested to dial in 10 minutes before the call to ensure a prompt start.

The following members of the CureVac team will participate on the call:

- Franz-Werner Haas, Deputy CEO
- Mariola Fotin-Mleczek, PhD, Chief Technology Officer
- Florian von der Mülbe, MBA, PhD, Chief Production Officer and Co-Founder
- Pierre Kemula, Chief Financial Officer
- Friedrich von Bohlen, PhD, Supervisory Board member, will participate on behalf of dievini Hopp BioTech holding.

**AGENDA:**

- Vaccines against coronavirus – medical need and challenges
- CureVac's approach
- Funding from public sources
- CureVac management update
- Q&A

We hope you will be able to join the call.

Kind regards

Thorsten Schüller,  
Head of Corporate Communications  
CureVac AG



### **About CureVac AG**

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

For more information, please visit [www.curevac.com](http://www.curevac.com) or follow us on Twitter at [@CureVacAG](https://twitter.com/CureVacAG).

### **CureVac Media Contact**

Thorsten Schüller, Head of Corporate Communications

Tel: +49 (0)7071 9883-1577

Email: [thorsten.schueller@curevac.com](mailto:thorsten.schueller@curevac.com)